Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Lung Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Smoking Cessation 1Motor Activity 1Inflammation 1Fatigue 1Endometrial Neoplasms 1Colonic Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 25Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × Hematologic Tests × Clear all
NCT03568188 2026-02-24

FOCALE

Hospices Civils de Lyon

Phase 2 Completed
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT02346526 2022-09-29

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Massachusetts General Hospital

Phase 2 Completed
22 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡